The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2020 | ZUMA series update: ZUMA-1 and ZUMA-2
Marie José Kersten, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, outlines the ZUMA-2 trial (NCT02601313), a phase II study evaluating the efficacy of brexucabtagene autoleucel, formerly KTE-X19, in patients with relapsed/refractory (R/R) mantle cell lymphoma. Additionally, Prof. Kersten discusses a comparison of ZUMA-1 (NCT02348216) and SCHOLAR-1 studies and highlights the importance of real world data. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
